MAP2K7 and melanoma: Although, oncogenic BRAF and NRAS mutations are usually mutually exclusive (66), they co-occur in approximately 7% of untreated melanoma and NRAS mutations confer resistance in 27% of BRAFV600-mutant melanoma patients who progress on combination BRAF and MEK inhibitor therapy (67).